At a glance
ClinicalIndex Comparison RecordPhase 1Recruiting· 72 target
Drug / intervention
C-CAR031 +3 morebiological
Likely dose
Not stated in record
Key inclusion· 14
- ✓Histologically confirmed hepatocellular carcinoma (HCC)
- ✓Barcelona Clinic Liver Cancer Stage B or C (BCLC B/C)
- ✓GPC3 possibly expressed in tumor tissues
- ✓Relapsed/progressive disease after at least one prior standard systemic therapy or ineligible/unable to tolerate systemic therapies
Key exclusion· 28
- ✕History of severe allergic or hypersensitivity to DMSO or known allergies to Lenvatinib, Regorafenib, or Durvalumab
- ✕History of liver transplantation
- ✕History of prior cell therapy
- ✕Tumor volume > 50% of liver
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
NCT05155189Phase 1RecruitingMonitorUpdated 5mo ago · Completion was 2mo agoSlow Enrollment
Long Recruiting
Monitor
A Clinical Study to Evaluate Safety and Efficacy of C-CAR031 Armored CAR-T Cell Injection in Treatment of Advanced Hepatocellular Carcinoma
In Brief
A Phase 1 clinical trial evaluating C-CAR031, Lenvatinib, and 2 other interventions for Hepatocellular Carcinoma. Currently recruiting, targeting 72 participants across 2 sites.
Signals
Enrolling slower than its timeline implies
Detailed Summary
A study that aimed to assess the safety and anti-tumor activity of CCAR031 injection in unresectable HCC patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatocellular Carcinoma
CountriesChina
Collaborators--
Timeline
Phase 1Recruiting
20222023202420252026202720282029203020312032203320342035203620372038203920402041
First PostedDec 2021
Enrollment StartFeb 2022
Primary CompletionMay 2026
TodayJul 2026
Study CompletionMay 2041
First PostedDec 13, 2021
Enrollment StartFeb 21, 2022
Primary CompletionMay 1, 2026
Study CompletionMay 1, 2041
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 4.6 years ago
Interventions
C-CAR031biological
Targeting GPC3 armored CART cell injection (C-CAR031)
Lenvatinibdrug
Tyrosine kinase inhibitors
Regorafenib (BAY 73-4506)drug
Tyrosine kinase inhibitors
Durvalumabdrug
Immune checkpoint inhibitors, ICIs